HTLV seroprevalence in people using HIV pre-exposure prophylaxis in England
Open Access
- 10 February 2023
- journal article
- research article
- Published by Elsevier in Journal of Infection
- Vol. 86 (3) , 245-247
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
This publication has 11 references indexed in Scilit:
- HTLV-1 Transmission and HIV Pre-exposure Prophylaxis: A Scoping ReviewFrontiers in Medicine, 2022
- Cabotegravir, the Long-Acting Integrase Strand Transfer Inhibitor, Potently Inhibits Human T-Cell Lymphotropic Virus Type 1 Transmission in vitroFrontiers in Medicine, 2022
- HIV PrEP is more than ART‐lite: Longitudinal study of real‐world PrEP services data identifies missing measures meaningful to HIV prevention programmingJournal of the International AIDS Society, 2021
- The demographic features and outcome indicators of the Barbados HIV Pre-exposure Prophylaxis Program, 2018-2019Revista Panamericana de Salud Pública, 2021
- Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studiesThe Lancet Infectious Diseases, 2020
- Interpretation of low reactivity in the Abbott Architect rHTLV I/II assayTransfusion Medicine, 2017
- Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialThe Lancet, 2016
- Seroprevalence of HTLV‐1 and HTLV‐2 amongst mothers and children in Malawi within the context of a systematic review and meta‐analysis of HTLV seroprevalence in AfricaTropical Medicine & International Health, 2015
- Human T‐cell lymphotropic virus antibody prevalence in HIV‐1‐infected individuals attending a sexual health clinic in South‐East LondonJournal of Medical Virology, 2005
- HTLV-I and HTLV-II infections among HIV-1 seropositive patients in Sao Paulo, BrazilEuropean Journal of Epidemiology, 1994